tiprankstipranks
Advertisement
Advertisement

VTGN Stock Latest News

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
Company AnnouncementsVistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
4d ago
VTGN
VistaGen Reaches Key Safety Milestone for Fasedienol Program
PremiumCompany Announcements
VistaGen Reaches Key Safety Milestone for Fasedienol Program
12d ago
8K
VTGN
Vistagen announces fasedienol achieves minimum patient exposures
PremiumThe Fly
Vistagen announces fasedienol achieves minimum patient exposures
12d ago
VTGN
VistaGen Appoints New Chief Medical Officer to Advance Pipeline
PremiumCompany Announcements
VistaGen Appoints New Chief Medical Officer to Advance Pipeline
1M ago
8K
VTGN
Vistagen appoints Angelov as Chief Medical Officer
PremiumThe Fly
Vistagen appoints Angelov as Chief Medical Officer
1M ago
VTGN
VistaGen Reports Positive Long-Term Data for Fasedienol
PremiumCompany AnnouncementsVistaGen Reports Positive Long-Term Data for Fasedienol
1M ago
8K
VTGN
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
Premium
The Fly
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
1M ago
VTGN
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
Premium
Company Announcements
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
1M ago
8K
VTGN
Vistagen announces completion of last patient visit in PALISADE-4 study
PremiumThe Fly
Vistagen announces completion of last patient visit in PALISADE-4 study
1M ago
VTGN
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
PremiumCompany Announcements
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
2M ago
8K
VTGN
AbCellera target is profile more attractive than Vistagen, says JonesResearch
PremiumThe Fly
AbCellera target is profile more attractive than Vistagen, says JonesResearch
2M ago
ABCL
VTGN
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
PremiumThe Fly
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
2M ago
VTGN
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
PremiumCompany AnnouncementsVistaGen Therapeutics Grants Broad Employee Retention Stock Options
2M ago
8K
VTGN
VistaGen Faces Nasdaq Audit Committee Compliance Setback
Premium
Company Announcements
VistaGen Faces Nasdaq Audit Committee Compliance Setback
3M ago
8K
VTGN
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
Premium
Company Announcements
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
3M ago
8K
VTGN
VistaGen Announces Workforce Reduction to Extend Cash Runway
PremiumCompany Announcements
VistaGen Announces Workforce Reduction to Extend Cash Runway
3M ago
8K
VTGN
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
PremiumClass Action
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
4M ago
VTGN
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
PremiumMarket News
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
4M ago
VTGN
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
PremiumClass Action
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
4M ago
VTGN
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
PremiumCompany AnnouncementsHigh-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
4M ago
VTGN
Vistagen Therapeutics Balances Progress and Uncertainty
Premium
Company Announcements
Vistagen Therapeutics Balances Progress and Uncertainty
4M ago
VTGN
Vistagen reports Q3 EPS (45c), consensus (49c)
Premium
The Fly
Vistagen reports Q3 EPS (45c), consensus (49c)
4M ago
VTGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >